Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

1.

Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3387-93. doi: 10.1016/j.bmcl.2010.04.015. Epub 2010 Apr 11.

PMID:
20451379
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, Cantley LC, Israelsen WJ, Vander Heiden MG, Shen M, Auld DS, Thomas CJ, Boxer MB.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6322-7. doi: 10.1016/j.bmcl.2011.08.114. Epub 2011 Sep 14.

PMID:
21958545
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Boxer MB, Jiang JK, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ.

J Med Chem. 2010 Feb 11;53(3):1048-55. doi: 10.1021/jm901577g.

PMID:
20017496
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.

Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG.

Nat Chem Biol. 2012 Oct;8(10):839-47. Erratum in: Nat Chem Biol. 2012 Dec;8(12):1008.

PMID:
22922757
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Serine is a natural ligand and allosteric activator of pyruvate kinase M2.

Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M, Gottlieb E.

Nature. 2012 Nov 15;491(7424):458-62. doi: 10.1038/nature11540. Epub 2012 Oct 14. Erratum in: Nature. 2013 Apr 18;496(7445):386.

PMID:
23064226
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Yacovan A, Ozeri R, Kehat T, Mirilashvili S, Sherman D, Aizikovich A, Shitrit A, Ben-Zeev E, Schutz N, Bohana-Kashtan O, Konson A, Behar V, Becker OM.

Bioorg Med Chem Lett. 2012 Oct 15;22(20):6460-8. doi: 10.1016/j.bmcl.2012.08.054. Epub 2012 Aug 23.

PMID:
22963766
[PubMed - indexed for MEDLINE]
7.

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG.

Cell. 2013 Oct 10;155(2):397-409. doi: 10.1016/j.cell.2013.09.025.

PMID:
24120138
[PubMed - indexed for MEDLINE]
8.

Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth.

Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY.

Mol Cell. 2011 Jun 24;42(6):719-30. doi: 10.1016/j.molcel.2011.04.025.

PMID:
21700219
[PubMed - indexed for MEDLINE]
Free Article
9.

Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Mazurek S.

Int J Biochem Cell Biol. 2011 Jul;43(7):969-80. doi: 10.1016/j.biocel.2010.02.005. Epub 2010 Feb 13. Review.

PMID:
20156581
[PubMed - indexed for MEDLINE]
10.

Identification of small molecule inhibitors of pyruvate kinase M2.

Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.

Biochem Pharmacol. 2010 Apr 15;79(8):1118-24. doi: 10.1016/j.bcp.2009.12.003. Epub 2009 Dec 11.

PMID:
20005212
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma.

Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO.

PLoS One. 2013;8(2):e57610. doi: 10.1371/journal.pone.0057610. Epub 2013 Feb 25.

PMID:
23451252
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis.

Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M.

Oncotarget. 2011 May;2(5):393-400.

PMID:
21789790
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Alteration in the capacities as well as in the zonal and cellular distributions of pyruvate kinase L and M2 in regenerating rat liver.

Chatzipanagiotou S, Nath A, Vogt B, Jungermann K.

Biol Chem Hoppe Seyler. 1985 Mar;366(3):271-80.

PMID:
4005043
[PubMed - indexed for MEDLINE]
14.

Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2.

Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, Wang Q.

Int J Mol Med. 2012 Aug;30(2):302-8. doi: 10.3892/ijmm.2012.989. Epub 2012 May 9.

PMID:
22580449
[PubMed - indexed for MEDLINE]
15.

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.

Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X.

Oncogene. 2011 Oct 20;30(42):4297-306. doi: 10.1038/onc.2011.137. Epub 2011 Apr 25.

PMID:
21516121
[PubMed - indexed for MEDLINE]
16.

Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis.

Lu Z.

Chin J Cancer. 2012 Jan;31(1):5-7. doi: 10.5732/cjc.011.10446. Epub 2011 Dec 23.

PMID:
22200182
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Tamada M, Suematsu M, Saya H.

Clin Cancer Res. 2012 Oct 15;18(20):5554-61. doi: 10.1158/1078-0432.CCR-12-0859. Review.

PMID:
23071357
[PubMed - indexed for MEDLINE]
Free Article
18.

New roles for pyruvate kinase M2: working out the Warburg effect.

Ferguson EC, Rathmell JC.

Trends Biochem Sci. 2008 Aug;33(8):359-62. doi: 10.1016/j.tibs.2008.05.006. Epub 2008 Jul 4.

PMID:
18603432
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death.

Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A.

Cancer Res. 2007 Feb 15;67(4):1602-8.

PMID:
17308100
[PubMed - indexed for MEDLINE]
Free Article
20.

Purified pyruvate kinases type M2 from unfertilized hen's egg are substrates of protein kinase C.

Noda S, Horn F, Linder D, Schoner W.

Eur J Biochem. 1986 Mar 17;155(3):643-51.

PMID:
3956503
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk